Novartis stock slips after UK patent win and strong Q2 2026
Published on 08/14/2026 at 07:52 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Novartis AG (CH0012005267) stock eased to $151.85 on August 13, 2026, after an extended-hours quote of $151.50 and a market value of $288.30 billion. Q2 2026 revenue reached $14.95 billion and adjusted EPS came in at $2.41, both above the same quarter a year earlier.
MarketBeat highlighted a news flow item on August 13, 2026 tied to Novartis winning a UK court challenge over the Entresto patent, while TradingKey also pointed to the same-quarter beat and improved full-year outlook. The combination leaves investors focused on how much of the recent strength is already reflected in the $151.85 close.
Patent protection matters
The Entresto ruling is important because patent durability still shapes the long-term cash flow profile for large drugmakers. Novartis reported a quarterly net margin of 23.29% and return on equity of 38.56%, figures that underline why margin protection continues to matter after the Q2 2026 beat.
Analyst sentiment has also been steady, with one market summary showing an average recommendation equivalent to Hold and a target of $144.15. That sits below the latest close and helps frame the stock's current valuation debate.
What the quarter showed
The latest quarter brought $14.95 billion in revenue, compared with $14.50 billion expected in one market summary, and earnings of $2.41 per share. The same data set also listed a 2026 full-year EPS view of 8.85, giving the market a fresh benchmark for the rest of the year.
TradingKey said the company lifted its outlook after the quarter, citing growth in oncology and immunology. For investors, that combination of a revenue beat, a higher earnings profile and a patent win is the clearest way to read the current setup.
Entresto and the pipeline
Entresto remains one of Novartis' best-known products, and the UK court outcome helps preserve that franchise's commercial visibility. The company also continues to lean on its broader drug pipeline, which market commentary has linked to the improved outlook after Q2 2026.
Novartis shares last closed at $151.85 on August 13, 2026, while the extended-hours quote was $151.50. The stock's 52-week range of $111.06 to $170.46 and market cap of $288.30 billion give the move a clear valuation frame.
More on Novartis stock
Novartis is a Swiss pharmaceutical group with a U.S. ADR under the ticker NVS and a broad portfolio spanning oncology, immunology and cardiovascular care. Entresto is one of the company's key products and remains central to the current patent discussion.
Market view
As of August 13, 2026, Novartis traded at $151.85 with a market cap of $288.30 billion and a 52-week range of $111.06 to $170.46.
Fact box
Company: Novartis AG
ISIN: CH0012005267
Ticker: NVS
Exchange: NYSE ADR
Price (as of August 13, 2026, 3:59 p.m. ET): $151.85 USD
Market cap: $288.30 billion (as of August 13, 2026)
Sector / Industry: Health Care / Pharmaceuticals
Index membership: S&P 500 not confirmed
Next earnings date: July 21, 2026
